ORIC Pharmaceuticals: Connecting with Investors
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a pioneering clinical-stage oncology company, is excited to announce its participation in several important investor conferences this November. Based in South San Francisco and San Diego, ORIC focuses on addressing the complexities of therapeutic resistance in cancer treatments.
Upcoming Conferences for ORIC Pharmaceuticals
The company's management team is slated to participate in the following investor events:
Guggenheim’s Inaugural Healthcare Innovation Conference
One of the highlight engagements will be at Guggenheim’s Inaugural Healthcare Innovation Conference, where ORIC's representatives will take part in a fireside chat scheduled for Monday, November 11, 2024, at 10:30 a.m. ET. This platform offers a unique opportunity to discuss innovative strategies aimed at overcoming challenges in oncology.
Jefferies London Healthcare Conference
Following that, on Thursday, November 21, 2024, ORIC Pharmaceuticals will also feature in a fireside chat during the Jefferies London Healthcare Conference at 12:00 p.m. GMT. Both events will be broadcasted live through ORIC’s investor section of their website, providing a chance for stakeholders and interested parties to gain insights directly from the experts.
Harnessing Technology for Better Cancer Treatments
As part of its mission to improve patients’ lives, ORIC Pharmaceuticals is committed to developing effective medicines that can tackle resistance mechanisms in cancer treatment. The company has a robust pipeline that includes promising candidates like:
ORIC-114
ORIC-114 is a cutting-edge brain penetrant inhibitor specifically targeting EGFR exon 20, HER2 exon 20, and atypical mutations of EGFR. This product is being developed for a variety of genetically defined cancers, allowing for tailored therapies that improve outcomes for patients.
ORIC-944
Another exciting candidate, ORIC-944, functions as an allosteric inhibitor toward the polycomb repressive complex 2 (PRC2). This drug is under development primarily for prostate cancer, showcasing ORIC’s dedication to addressing diverse cancer types.
ORIC-533
Along with these, ORIC is pioneering ORIC-533, an orally bioavailable small molecule that inhibits CD73, a critical component involved in the adenosine pathway. This drug is aimed at multiple myeloma, and its development reflects ORIC Pharmaceuticals' strategic focus on overcoming resistance encountered in both chemotherapy and immunotherapy.
Commitment to Research and Development
With a portfolio that extends beyond just these three candidates, ORIC is dedicated to exploring and developing more precision medicines that target significant resistance mechanisms in cancer. They are poised to make substantial contributions to oncology, driven by innovative research and the desire to meet the needs of patients facing these devastating diseases.
Staying Connected with Stakeholders
For those unable to attend the conferences live, ORIC Pharmaceuticals will make webcasts of the discussions accessible for 90 days post-event, ensuring everyone can stay informed about their groundbreaking work. Interested parties can find further information on their official website.
Contact Information for ORIC Pharmaceuticals
For additional inquiries or further details, the public can reach out to:
Dominic Piscitelli
Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
Frequently Asked Questions
What is the focus of ORIC Pharmaceuticals?
ORIC Pharmaceuticals is focused on developing innovative treatments to combat cancer resistance mechanisms.
What conferences is ORIC Pharmaceuticals participating in?
ORIC is participating in Guggenheim’s Healthcare Innovation Conference and the Jefferies London Healthcare Conference this November.
What are ORIC’s noteworthy product candidates?
Key candidates include ORIC-114, ORIC-944, and ORIC-533, tackling various cancer types through novel mechanisms.
How can stakeholders access ORIC's conference webcasts?
Stakeholders can access the webcasts of the discussions on ORIC’s investor section of their official website for 90 days after the events.
Who should I contact for more information about ORIC Pharmaceuticals?
Contact Dominic Piscitelli, Chief Financial Officer, via email for further inquiries.
